Literature DB >> 2835329

Clinical and research application of an enterovirus group-reactive monoclonal antibody.

G E Yousef1, G F Mann, I N Brown, J F Mowbray.   

Abstract

Diagnostic methods employed in enterovirus laboratories are generally laborious, slow and expensive. This is largely because type-specific neutralization tests still play the major role in identification and diagnostic serology. In the companion paper we describe the derivation of monoclonal antibodies against epitopes of the VPI peptide which are shared by all of the enteroviruses tested to date, with the exception of hepatitis A virus. This study describes the application of one of these monoclonal antibodies in several research and diagnostic procedures, illustrating a special utility in a wide variety of assay systems. This monoclonal antibody has proved particularly useful in the detection of enterovirus antigens in circulating immune complexes, and in identifying field isolates of this group of viruses. Immunohistochemistry, previously almost impossible in enterovirus diagnosis and research due to the large number of serotypes, is now shown to be practical and informative when this monoclonal antibody is used.

Mesh:

Substances:

Year:  1987        PMID: 2835329     DOI: 10.1159/000150017

Source DB:  PubMed          Journal:  Intervirology        ISSN: 0300-5526            Impact factor:   1.763


  11 in total

1.  Spectrum of monoclonal antibodies to coxsackievirus B-3 includes type- and group-specific antibodies.

Authors:  S Yagi; D Schnurr; J Lin
Journal:  J Clin Microbiol       Date:  1992-09       Impact factor: 5.948

2.  Detection of enteroviruses from clinical specimens by spin amplification shell vial culture and monoclonal antibody assay.

Authors:  S L Klespies; D E Cebula; C L Kelley; D Galehouse; C C Maurer
Journal:  J Clin Microbiol       Date:  1996-06       Impact factor: 5.948

Review 3.  Molecular typing of enteroviruses: current status and future requirements. The European Union Concerted Action on Virus Meningitis and Encephalitis.

Authors:  P Muir; U Kämmerer; K Korn; M N Mulders; T Pöyry; B Weissbrich; R Kandolf; G M Cleator; A M van Loon
Journal:  Clin Microbiol Rev       Date:  1998-01       Impact factor: 26.132

4.  Monoclonal antibodies for clinical applications. Patents and literature.

Authors:  J S Dordick
Journal:  Appl Biochem Biotechnol       Date:  1988-12       Impact factor: 2.926

5.  Evaluation of an enterovirus group-specific anti-VP1 monoclonal antibody, 5-D8/1, in comparison with neutralization and PCR for rapid identification of enteroviruses in cell culture.

Authors:  A Trabelsi; F Grattard; M Nejmeddine; M Aouni; T Bourlet; B Pozzetto
Journal:  J Clin Microbiol       Date:  1995-09       Impact factor: 5.948

6.  Rapid shell vial culture technique for detection of enteroviruses and adenoviruses in fecal specimens: comparison with conventional virus isolation method.

Authors:  G J Van Doornum; J C De Jong
Journal:  J Clin Microbiol       Date:  1998-10       Impact factor: 5.948

7.  A new monoclonal antibody (Cox mAB 31A2) detects VP1 protein of coxsackievirus B3 with high sensitivity and specificity.

Authors:  Nicole Ettischer-Schmid; Andrea Normann; Martina Sauter; Lisa Kraft; Hubert Kalbacher; Reinhard Kandolf; Bertram Flehmig; Karin Klingel
Journal:  Virchows Arch       Date:  2016-08-27       Impact factor: 4.064

8.  Epidemiology of enterovirus 71 in the Netherlands, 1963 to 2008.

Authors:  Sabine van der Sanden; Marion Koopmans; Gökhan Uslu; Harrie van der Avoort
Journal:  J Clin Microbiol       Date:  2009-07-22       Impact factor: 5.948

9.  Dynamin- and lipid raft-dependent entry of decay-accelerating factor (DAF)-binding and non-DAF-binding coxsackieviruses into nonpolarized cells.

Authors:  Kunal P Patel; Carolyn B Coyne; Jeffrey M Bergelson
Journal:  J Virol       Date:  2009-08-26       Impact factor: 5.103

Review 10.  Role of the virology laboratory in diagnosis and management of patients with central nervous system disease.

Authors:  T Chonmaitree; C D Baldwin; H L Lucia
Journal:  Clin Microbiol Rev       Date:  1989-01       Impact factor: 26.132

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.